Page 8 - SFRBMdot - December 2014

SUPPORTERS

FASEB

SFRBM wishes to express its gratitude to the following institutions and

companies that ensured the success of SFRBM 2014.
CORNER

INNOVATIVE RESEARCH

(A minimum $5,000 contribution to support Annual Meeting Programming)
I attended the FASEB Board of

Directors meeting in Washington

DC in early December as the SFRBM

representative. Given SFRBM’s new

afiliation with FASEB, it was the

irst time we have had an in-person

Harry Ischiropoulos, seat at the table with 26 other
Ph.D.
societies who are all interested in

positively inluencing law and policymakers about

the importance of biomedical science research. It’s

important to recognize that SFRBM has something

important to offer FASEB - we offer a consolidated

representation of the redox biology, antioxidant and

free radical chemistry research segment which is truly

unique among their current member societies.

Strength can deinitely be found in numbers - there

are over 120,000 scientists (including 100+ Nobel

laureates) that are part of FASEB’s member societies.

FASEB has developed a solid working relationship

with the congressional appropriation committee

YOUNG INVESTIGATOR
members and they appreciate that FASEB provides

(A minimum $2,500 contribution to support Annual Meeting Programming)
data and presents fact-based, reasonable positions

and proposals on various issues.

FASEB’s highest priority at the moment is to circulate a

consolidated research statement to key stakeholders
Free Radical and Radiation Biology Program
IOWA
in Congress, NIH/NSF and DOD. SFRBM has provided

input to that statement. The FASEB website will be

2
undergoing a “make over” since it is rather busy at
At the forefront of redox biology, free radical and cancer research
present and hard to ind important information. As an

example, FASEB has developed nice advocacy tools

all investigators can use but are currently dificult to

locate. FASEB works with other advocate groups,

since as the Coalition for Life Sciences and advocate

patient groups, however it is not a priority.

SFRBM Newsletter // December 2014 // SFRBM 2014

8 IN THIS ISSUE V I S I T U S O N L I N E : W W W . S F R B M . O R G